Evidence map›Paper›PMID 32315100›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2020

Design and Synthesis of 56 Shape-Diverse 3D Fragments.

Thomas D Downes, S Paul Jones, Hanna F Klein, Mary C Wheldon, Masakazu Atobe, Paul S Bond, James D Firth, Ngai S Chan, Laura Waddelove, Roderick E Hubbard and 8 more

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Synthesis of spOrganic & biomolecular chemistry · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Thomas D DownesDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID http://orcid.org/0000-0002-6409-8831
S Paul JonesDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID http://orcid.org/0000-0003-2873-7031
Hanna F KleinDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID http://orcid.org/0000-0003-0133-3790
Mary C WheldonDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.
Masakazu AtobeDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID http://orcid.org/0000-0002-7314-0237
Paul S BondDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID http://orcid.org/0000-0002-8465-4823
James D FirthDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID http://orcid.org/0000-0003-2283-552X
Ngai S ChanDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.
Laura WaddeloveDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.
Roderick E HubbardDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID http://orcid.org/0000-0002-8233-7461
David C BlakemoreMedicine Design, Pfizer Inc, 445 Eastern Point Road, Groton, CT 06340, USA.
Claudia De FuscoDiscovery Sciences, R&D, AstraZeneca, Cambridge, CB4 0WG, UK.ORCID http://orcid.org/0000-0001-8807-4976
Stephen D RoughleyVernalis (R&D) Ltd, Granta Park, Abington, Cambridge, CB21 6GB, UK.ORCID http://orcid.org/0000-0003-0683-5693
Lewis R VidlerEli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK.ORCID http://orcid.org/0000-0002-8742-293X
Maria Ann WhattonEli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK.
Alison J-A WoolfordAstex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA, UK.
Gail L WrigleyMedicinal Chemistry, Oncology R&D, AstraZeneca, CB4 0WG, Cambridge, UK.
Peter O'BrienDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID http://orcid.org/0000-0002-9966-1962

Funding

Biotechnology and Biological Sciences Research Council BB/N008332/1Engineering and Physical Sciences Research CouncilHorizon 2020 Framework Programme 675899, FRAGNETWellcome Trust
6 · The paper itself

Abstract

Fragment-based drug discovery is now widely adopted for lead generation in the pharmaceutical industry. However, fragment screening collections are often predominantly populated with flat, 2D molecules. Herein, we describe a workflow for the design and synthesis of 56 3D disubstituted pyrrolidine and piperidine fragments that occupy under-represented areas of fragment space (as demonstrated by a principal moments of inertia (PMI) analysis). A key, and unique, underpinning design feature of this fragment collection is that assessment of fragment shape and conformational diversity (by considering conformations up to 1.5 kcal mol

Indexed as

3D fragmentsconformational diversityfragment-based drug discoverymedicinal chemistrysynthesis design

Identifiers

PMID32315100
PMCPMC7496344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.